Clinical Trial Update: 12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation [Phase 2]

View source ↗

Summary

A Phase 2 trial from Pfizer evaluated the safety and efficacy of three doses of CP-526,555 versus placebo for smoking cessation over 12 weeks; the study has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence

Drugs mentioned

• CP-526,555

Snippet

Sponsor: Pfizer | Conditions: Smoking Cessation | Phase 2 | Status: COMPLETED